XTL BIOPHARMACEUTICALS LTD | 4,38 Euro | -0,078 -1,75 % | |
| WKN: A1J5TP ISIN: US98386D2080 Ticker-Symbol: H2K1 | Frankfurt | 24.05.13 | 15:37 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 05.12. | Following the Acquisition of the Controlling Stake by XTL, Proteologics Appoints Board Members and Chairman | 88 | PR Newswire | |
| HERZLIYA, Israel, December 5, 2012 /PRNewswire/ --
XTL Biopharmaceuticals Ltd (TASE: XTL) (OTC: XTLBY) (the "Company", or "XTL"), a biopharmaceutical development company that recently acquired the... Mehr lesen zu: Following the Acquisition of the Controlling Stake by XTL, Proteologics Appoints Board Members and Chairman | ||||
| 27.11. | XTL Biopharmaceuticals buys Proteologics shares | 1 | Pharma Bus Review | |
| 26.11. | XTL Biopharma Buys Stake in Proteologics from Teva | - | Benzinga.com | |
| 26.11. | XTL Biopharma Acquires Teva's (TEVA) Stake in Proteologics | 1 | StreetInsider.com | |
| 26.11. | XTL Biopharmaceuticals Acquires Stake in Proteologics Ltd. | 80 | PR Newswire | |
| HERZLIYA, Israel, November 26, 2012 /PRNewswire/ --
XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced on November 21st that... Mehr lesen zu: XTL Biopharmaceuticals Acquires Stake in Proteologics Ltd. | ||||
| 05.10. | XFRA FRA:New Instruments available on XETRA - 05.10.2012-001 | 137 | Xetra Newsboard | |
| The following instruments on XETRA do have their first trading day
05.10.2012
Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am
05.10.2012
TrdMod InstCode Exch ISIN Name InstGrp... Mehr lesen zu: XFRA FRA:New Instruments available on XETRA - 05.10.2012-001 | ||||
| 04.10. | XTL Biopharmaceuticals Effectuates ADR Ratio Change | 38 | PR Newswire | |
| HERZLIYA, Israel, October 4, 2012 /PRNewswire/ --
XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced today that following the... Mehr lesen zu: XTL Biopharmaceuticals Effectuates ADR Ratio Change | ||||
| 04.10. | XFRA FRA: DELETION OF INSTRUMENTS FROM XETRA - 04.10.2012 | 348 | Xetra Newsboard | |
| The following instruments on XETRA do have their last trading day on
04.10.2012
Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am
04.10.2012
ISIN Name
CA0079752048 AETERNA... Mehr lesen zu: XFRA FRA: DELETION OF INSTRUMENTS FROM XETRA - 04.10.2012 | ||||
| 04.10. | XFRA H2K, NBT, ET8: AENDERUNG / CHANGE ISIN | 199 | Xetra Newsboard | |
| FUER FOLGENDE INSTRUMENTE WERDEN ISIN. WKN UND KUERZEL GEAENDERT. GUELTIG
AB 05.10.2012
FOR THE FOLLOWING INSTRUMENTS ISIN, WKN AND SHORT CODE WILL CHANGE. VALID
FROM OCTOBER 05, 2012
EINSTELLUNG... Mehr lesen zu: XFRA H2K, NBT, ET8: AENDERUNG / CHANGE ISIN | ||||
| 04.10. | XFRA H2K: AUSSETZUNG/SUSPENSION | 97 | Xetra Newsboard | |
| DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT:
THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
XTL BIOPHARMA. ADR 2 H2K US98386D1090 BAW/UFN Mehr lesen zu: XFRA H2K: AUSSETZUNG/SUSPENSION | ||||
| 04.10. | XFRA CAPITAL ADJUSTMENT INFORMATION - 04.10.2012 - 2 | 170 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 04.10.2012 EX KAPITALMASSNAHME GEHANDELT.
THE FOLLOWING SHARES ARE TRADED EX CAPITAL ADJUSTMENT ON 04.10.2012.
INSTR EXCH ISIN INSTRUMENT NAME
H2K XFRA US98386D1090... Mehr lesen zu: XFRA CAPITAL ADJUSTMENT INFORMATION - 04.10.2012 - 2 | ||||
| 24.09. | Strategic Online Marketing Agreement signed by InterCure, XTL Biopharmaceuticals' Subsidiary | 39 | PR Newswire | |
| HERZLIYA, Israel, September 24, 2012 /PRNewswire/ --
XTL Biopharmaceuticals Ltd. ("XTL") today announced that InterCure Ltd. ("InterCure"), which is approximately 45.4% (50.79% on a fully diluted... Mehr lesen zu: Strategic Online Marketing Agreement signed by InterCure, XTL Biopharmaceuticals' Subsidiary | ||||
| 24.09. | XTL Biopharmaceuticals Provides Favorable Update on NASDAQ Listing Process | 21 | PR Newswire | |
| HERZLIYA, Israel, September 24, 2012 /PRNewswire/ --

XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced today that it has... Mehr lesen zu: XTL Biopharmaceuticals Provides Favorable Update on NASDAQ Listing Process | ||||
| 19.06. | XTL Biopharmaceuticals to Acquire Kitov Pharmaceuticals | 17 | PR Newswire | |
| HERZLIYA, Israel, June 19, 2012 /PRNewswire/ --
XTL Biopharmaceuticals Ltd. (TASE:XTL)(OTC:XTLBY),a biopharmaceutical development company, announced today it will acquire Kitov Pharmaceuticals Ltd.... Mehr lesen zu: XTL Biopharmaceuticals to Acquire Kitov Pharmaceuticals | ||||
| 11.06. | XTL Biopharmaceuticals Joins Two Additional Indexes on TASE | 39 | PR Newswire | |
| HERZLIYA, Israel, June 11, 2012 /PRNewswire/ --
XTL Biopharmaceuticals Ltd. (TASE:XTL,OTC:XTLBY), a biopharmaceutical development company, announces it has been notified by the Tel Aviv Stock Exchange... Mehr lesen zu: XTL Biopharmaceuticals Joins Two Additional Indexes on TASE | ||||
| 04.06. | XTL Biopharmaceuticals Files Application for Listing on the NASDAQ | 34 | PR Newswire | |
| HERZLIYA, Israel, June 4, 2012 /PRNewswire/ --
XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced today that it has filed an... Mehr lesen zu: XTL Biopharmaceuticals Files Application for Listing on the NASDAQ | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| ADVANCED CELL TECHNOLOGY | 0,054 | -1,82 % | Advanced Cell Technology, Cytomedix and Mesoblast to Provide Corporate and Clinical Updates at Regen Med Investor Day |
| MEDIGENE | 0,93 | +4,61 % | Medigene: Rating wird erneuert |
| VICAL | 2,79 | +4,49 % | VICAL INC - 8-K, Current Report |
| EVOTEC | 2,75 | -0,58 % | Evotec-Aktie: Jetzt einsteigen! |
| XOMA | 3,163 | +3,54 % | Ladenburg hebt das Kursziel für XOMA von $5 auf $6. |
